• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BOT

BOTANIX PHARMACEUTICALS LTD - News & Media

5.26% ! 2.0¢
Market Cap $51.95M  !
Healthcare
Add to My Watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Articles & Videos

Last year's anti-sweat biotech darling Botanix falls -10% on poorly received quarterly

Botanix Pharma (ASX:BOT) saw its share price fall around -10% on Tuesday as the company’s latest quarterly update, in which sales of its anti-chronic-sweating drug Sofdra are in the spotlight, failed to impress investors (who are likely, in Botanix’s defence, payin...

27 Jan 2026 14:36 (AEDT)

Botanix jumps back above 15cps on '65%' revenue growth to $7M; new sales force boost

Botanix latest quarterly earnings report showed that revenues from anti-sweating drug Sofdra have increased to $7.1 million.

20 Oct 2025 12:31 (AEDT)

Maybe sweat the small stuff: Botanix underwhelms, falls -40%

The problem with building big valuation expectations on the treatment of rare diseases is that you either need expensive drugs, or, some kind of government support, because a rare disease, by its very nature, implies a small addressable market.Listen to the HotCopper podcast for in-depth discussi...

08 Jul 2025 11:22 (AEST)

First Sofdra prescriptions for excessive sweating condition pushes Botanix towards full commercial launch

Botanix has reported the first prescriptions of its drug Sofdra (sofpironium) to treat hyperhidrosis, a condition of excessive sweating.

17 Dec 2024 10:25 (AEDT)

US FDA approves Botanix Pharma's excessive underarm sweat drug

Botanix on Thursday described itself as having transitioned from a development stage to being revenue-generating dermatology company.

20 Jun 2024 10:56 (AEST)

Botanix isn't sweating on FDA approval for Sofdra

Botanix has submitted the last label materials to the FDA seeking approval for Sofdra™ a prescription treatment for underarm sweating.

12 Jun 2024 09:49 (AEST)

Botannix Pharmaceuticals' resubmission of Sofdra NDA accepted by FDA

Botannix Pharmaceuticals' (ASX:BOT) resubmission of the new drug application for Sofdra has been accepted by the FDA as a complete response.

22 Jan 2024 12:04 (AEDT)

Botanix Pharmaceuticals completes HF validation study for Sofdra, eyes FDA approval by mid-2024

Botanix Pharmaceuticals (ASX:BOT) has completed the planned human factors (HF) validation study for Sofdra, evaluating revised instructions for use (IFU).

14 Dec 2023 11:53 (AEDT)

FDA greenlights Botanix Pharmaceuticals' Sofdra resubmission plan

FDA approves Botanix's strategy for Sofdra NDA resubmission with no additional materials requested, keeping submission to Q1 CY2024.

04 Dec 2023 10:08 (AEDT)

Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Botanix Pharmaceuticals (ASX: BOT) has closed its $13.5 million placement to both new and existing institutional and sophisticated investors to accelerate commercial activities in the US to increase revenue turnaround.

01 Dec 2023 11:50 (AEDT)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
Start T rading
Last
2.0¢ 		Change
0.001(5.26%) 		Mkt cap ! $51.95M
Open High Low Volume
2.0¢ 2.0¢ 1.9¢ 981.5K

Buyers (Bids)

Vol. Price($)
8025378 1.9¢
 

Sellers (Offers)

Price($) Vol.
2.0¢ 1631777
Last trade - 10.14am 03/08/2026 (20 minute delay) ?
BOT (ASX) Chart

Top Stories

Diablo expands critical minerals footprint at Star Range

Welcome to HotCopper’s latest Watchlist, where this week we’ve been joined by Diablo Resources (ASX:DBO) CEO Lyle Thorne to discuss recent exploration that’s @expanded the scale” at Star Range in Beaver County, Utah.Listen to t...
Prairie Lithium advances towards first production as commercial DLE unit arrives Prairie Lithium (ASX:PL9) has reached a major milestone in its path to first production, with North America’s largest commercial Direct Lithium Extraction (DLE) unit now delivered to site in Saskatchewan. The arrival marks the start of installation as the ASX-listed company moves ...
Expert Exchange: The Kouk on Michelle Bullock's legacy as RBA Governor Economist Stephen Koukoulas breaks down Michele Bullock's RBA legacy so far and what her final years as Governor could mean for Aussies.
Klevo Rewards advances stablecoin strategy with credit licence acquisition Klevo Rewards CEO Alexander Gold talks to HotCopper about officially completing the acquisition of an Australian credit licence.
AFT Pharmaceutical's multi-billion R&D opportunity Welcome to HotCopper’s latest Watchlist, where we’ve been joined by AFT Pharmaceuticals (ASX:AFP) founder and chief executive Hartley Atkinson to discuss its expanding global reach and the @tentative” FDA approval the company has just hauled i...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.